america corp bac
america earn prep
first take
jnj earn read coverag
large-cap bank support rel call
jpm-wfc card healthi acceler balance/spend competit auto
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result
investor awar firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price month
medic ceo transit stephen mason current presid cah at-hom solut
busi assum role ceo medic follow jon giacomin departur mid-
august note giacomin depart becom ceo privately-held compani
year current role year challeng medic experi follow
difficult cordi integr acquir octob giacomin task improv
execut complet integr process note improv cordi
perform increas fill rate declin backord overal medic result
disappoint follow choppi patient recoveri tsa exit continu commod
headwind recent announc inher drive investor concern
medic result outlook affirm expect least meet
midpoint ep guidanc line estim consensu
maintain ep estim
cfo updat cah search perman cfo remain underway compani aim
find replac relev industri public compani experi financ
team fairli deep offer support ceo michael kauffman assum addit role
interim cfo cfo fli coop seemingli look experienc execut
view encourag remind cfo jorg gomez depart effect aug
becom cfo outperform previou medic segment
experi prior relationship xray ceo like motiv move gomez
particip cah ep call august
date product utc date dissemin utc
america corp bac
america earn prep
america report first thing tomorrow/wednesday estim per share
consensu expect revenu come shi yr/yr flat qtr/qtr
multipl macro market influenc weigh inglob bank market
challeng comparison year ago quarter global wealth invest manag
benefit fulli asset price appreci solid growth expect consum
bank expens ought flat yr/yr track full year assum
flattish provis stabl loss rate forecast result would translat rotc
cet
price month
matter most/import discuss point forward look manag take
macro backdrop global growth capit market health credit qualiti migrat
cours cost yield curv shift ii organ revenu momentumloan deposit growth
consum bank net asset inflow gwim market share trend across gcib iii
expens management/assum outlook hold flattish expens year next iv
capit market health loan deposit flows/pricingexpect outperform
latterdeposit beta forward assumptionsfair expect temper nii
date product utc date dissemin utc
first take
price month
ep miss comp ep sell-sid consensu
estim beat larg driven lower tax rate lower net interest
expens partial off-set pre-tax loss relat sale corpor ny
store report drag us compstore compani franchis
rel sell-sid consensu believ market expect closer
intern compstore acceler rel consensu company-
oper margin improv includ improv labor margin part
relat refranchis transact stock pre-market trade
question conf call et id
composit us intern compstore traffic vs ticket compstore drag
fortress strategi quarter drag point piespromo
earli repres compstore drag chang impact
third-parti deliveri aggreg us intern compstore rel prior quarter
refranchis corpor ny store affect company-oper margin
updat regard time open new suppli chain center chang
franchise sentiment profit
link preview point comp earn preview
date product utc date dissemin utc
approach earn season look top question face refin sector
individu compani believ know answer question help investor get
better grip refin macro well pick winner within refin top sector-specif
question
run much light impact captur rate given scarciti
heavi sour market abund light sweet crude us refin continu
lighten feed slate howev run light especi super light increas ngl
naphtha output trade steep discount gasolin diesel price
impact captur refin would like hear refin run
issu work around
gulf coast heavi sour problem gc market remain tight come
avail heavi sour barrel brent-maya diff coke econom
pemex cut factor definit help august canadian rail
ramp expect lot wc reach gc year-end estim still
risk neg revis given tough start quarter
drove turnaround gasolin market start gasolin
inventori yoy last year level earlier
gasolin bear express concern util ramp gasolin inventori could build
howev last shown gasolin inventori continu draw
even refineri util hit would curiou know refin
drove turnaround market
imo resid forward curv move right direct spread
brent resid final start move right direct spread
continu narrow last year narrow spread impli lower perceiv posit
impact imo refin earn resid spread april
one year ago narrow one month ago last week
spread re-widen view posit curiou know
refin still believ resid fuel price start collaps
normal earn power retail segment last quarter seen
lot volatil market segment earn neither bloat retail margin
except weak normal quarter retail busi expect
deliv significantli higher qoq retail earn give us better
idea normal earn power market segment
company-specif question also cover company-specif question report pleas check
individu compani page detail
date product utc date dissemin utc
data-point channel check within commerci auto industri continu point
weaken shipment volum ultim caus truck employ soft
translat moder loss-infl trend insur grappl increas
accid frequenc sever larg attribut less skill driver road
recent headlin sum dynam take fold least truck driver lost
job transport bloodbath unfold busi insid juli
recal one reason bullish upgrad outperform
portfolio remix harden reinsur price view take advantag
improv commerci auto condit re-coup lost market share first flag
improv backdrop insur past may worst behind regul still steer
date product utc date dissemin utc
jnj earn read coverag
highlight key drugs/program johnson johnson earn relev
jnj remicad qoq due biosimilar competit increas
discounts/reb highlight increas competit blockbust drug
new opportun biosimilar report geographi remicad
vs believ biosimilar repres potenti upsid case
compani biosimilar approv develop recal submit bla
abp biosimilar remicad could see long-term biosimilar sale
exceed gener guidanc compani provid franchis estim
given abil leverag exist infrastructur lower cost
biosimilar broader implic point toward eros brand blockbust drug
amgen enbrel abbvi humira view us biosimilar opportun repres
import opportun legal hurdl surpass sandoz district court rule
decis expect day could provid import preced could affect brand
drug face similar lawsuit biosimilar link analysi potenti enbrel ip outcom
jnj balversa launch on-going recent approv provid signific head start
incyt pemigatinib balversa erdafitinib oral fgfr kinas inhibitor use urotheli
cancer uc approv mid-april fda accord evalu pharma balversa
project achiev us sale launch on-going year head
start pemigatinib project could launch late pemigatinib phase
trial uc modifi includ continu dose regimen initi
start intermitt dosingth trial design start intermitt switch
continu use balversa believ like make sens perform addit
studi ensur data optim howev result delay give addit time
market project unadjust ww sale pemigatinib uc
includ cholangiocarcinoma approv believ pemigatinib could
help drive next leg growth drug like face challeng compet
balversa given signific lead market reiter neutral rate
date product utc date dissemin utc
large-cap bank support rel call
mortgag consum credit trend jp morgan well fargocov
css susan katzkesuggest solid acceler mortgag trend consum credit
line support posit view stock mortgag origin
revenu revenuewer yoy vs cs bank
expect yoy eop credit card loansefx consum
credit ecosystemwer yoy rel cs bank expect
increment posit data point see mortgag trend meaning read-
across vs credit card loan credit demand overshadow
mortgag origin believ in-lin credit demand consist late-
cycl select view said believ discount efx valuat
would strateg scale posit weak see return normal growth
eas breach overhang key multipl expans driver
mortgag revenu mortgag banker associ project
mortgag origin yoy includ boost purchas increas
refin
consum credit revenu credit card loan rose yoy
jpm/wfcan acceler
respect believ consist late-cycl economi lead
expn trade miss impact truexpn grobler report
organ growth come consensu low-end guidanc
said compani maintain fy organ growth guidanc highlight underwhelm uk uk
ireland group revenu growth organ neg read-
across uk revenu given callcredit acquisitionin view
somewhat off-set strong us north america group revenu revenu though
segment mix revenu deceler rel acceler
prefer rel basisfollow guid re-affirmed last
quarterachiev vieww continu see progress normal revenu
growth time drive multipl margin expans amid margin-enhanc
infrastructur improv surfac
date product utc date dissemin utc
earlier today third-parti data forecast ih automot releas monthli updat light
vehicl product lvp forecast note recent initi coverag us
autossector see clock near cyclic keen focu investor given
choppi end-market weve face expect ih cut global industri product forecast
driven primarili china continu cycl neg revis began year ago
hope worst ofth neg revis cycl estim
beyond year continu expect no-growth industri outlook volatil risk
downsid take releas follow
global lvp end y/i vs prior forecast forecast
go cut driven primarili china vs prior forecast
neg china product reflect challeng sale environ well
destock na europ close unchang vs prior forecast nevertheless
neg quarter europ lvp na lvp
revis yet neg revis like necessari china ih revis
forecast global lvp y/i vs prior vs
prior driven larg china china forecast vs prior europ
saw neg revis forecast y/i na saw neg revis
forecast hope pass worst neg revis
cycl industri product estim note still downsid risk china
forecast flat growth like need come assum neg
environ assum china product
forecast revis yet downsid expect china estim
global lvp forecast y/i vs prior within china growth forecast
vs prior yet see downsid estim assum flat
environ
platform line expect platform end
product ford f-seri product end benefit
easi comp drag meridian fire platform saw final product
larg line expect go furthermor expect platform
remain consist forecast y/i
f-seri forecast
date product utc date dissemin utc
jpm-wfc card healthi acceler
balance/spend competit auto student
takeaway view strong credit card spend growth acceler
indic rebound growth trend low level posit delinqu trend
small delinqu format signific loan growth acceler ytd
view sign health credit qualiti card issuer jpm card revenu rate
continu show improv last year
auto origin acceler y/i could modest neg auto
lender particularli use subprim student origin y/i mani
quarter declin led refin volum offer refi product though season
light relev
strong spend growth acceler card loan growth seen signific
acceler purchas volume grew y/i versu vs y/i growth rate
 est y/i credit debit
y/i credit debit note time year could play
small part acceler purchas volume growth jpm loan bal y/i growth
acceler nice jpm merchant servic volum growth vs
growth y/i growth
 report earn yesterday saw acceleration/deceler card balanc purchas
volum growth brand cards/priv label respect credit qualiti card busi
remain stabl
dq slightli continu credit loss bp y/i
vs bp y/i prior quarter note management expect card loss rate
stabl level day dq bp y/i compar increas
bp y/i last quarter built mil card reserv quarter driven growth
mix bit higher mil reserv build
auto volume rise revers trend volume acceler origin
y/i vs y/i origin grew vs y/i
y/i nco rate better vs last year continu
emphas qualiti day dq rate vs last year dq rate
declin y/i nco rate vs last year dq rate vs last
student well origin increas student loan refi student origin
increas y/i compar increas driven higher refin
origin though season smaller quarter look gaug
impact credit stabl modest increas dq
date product utc date dissemin utc
charl martineau pm univers toronto compani mention price
america corp bac
